Jagsonpal Pharmaceuticals Ltd Stock Price Today (NSE: JAGSNPHARM)
Fundamental Score
Jagsonpal Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Jagsonpal Pharmaceuticals Ltd share price today is ₹209.19, down 0.03% on NSE/BSE as of 17 June 2026. Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.45K (Cr). The 52-week high for JAGSNPHARM share price is ₹301.65 and the 52-week low is ₹155.00. At a P/E ratio of 33.23x, JAGSNPHARM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 18.58% and a debt-to-equity ratio of 0.03.
Jagsonpal Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Jagsonpal Pharmaceuticals Ltd share price chart: -5.23% return over the past month. 52-week high ₹301.65, 52-week low ₹155.00.
Jagsonpal Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹202.10 | ₹203.89 | ₹200.00 | ₹201.74 | 24.46K (Cr) | |
| ₹207.90 | ₹208.40 | ₹200.10 | ₹201.60 | 40.04K (Cr) | |
| ₹210.00 | ₹212.90 | ₹206.00 | ₹206.60 | 43.25K (Cr) | |
| ₹207.89 | ₹212.00 | ₹202.00 | ₹209.02 | 1.96L (Cr) | |
| ₹207.00 | ₹212.80 | ₹205.21 | ₹207.89 | 96.20K (Cr) | |
| ₹210.05 | ₹212.37 | ₹200.01 | ₹205.69 | 1.47L (Cr) | |
| ₹213.96 | ₹213.96 | ₹208.00 | ₹209.92 | 1.99L (Cr) | |
| ₹198.60 | ₹214.05 | ₹196.97 | ₹211.84 | 3.91L (Cr) | |
| ₹196.43 | ₹208.20 | ₹194.61 | ₹199.31 | 63.77K (Cr) | |
| ₹201.07 | ₹203.50 | ₹196.00 | ₹197.22 | 63.66K (Cr) |
Jagsonpal Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹207.90 | ₹208.40 | ₹200.00 | ₹201.74 | -2.96% | |
| ₹206.37 | ₹225.12 | ₹194.61 | ₹206.60 | +0.11% | |
| ₹185.80 | ₹213.70 | ₹184.00 | ₹210.37 | +13.22% | |
| ₹165.30 | ₹201.50 | ₹157.55 | ₹184.03 | +11.33% | |
| ₹169.00 | ₹188.00 | ₹163.70 | ₹168.67 | -0.20% | |
| ₹193.57 | ₹195.00 | ₹155.00 | ₹168.82 | -12.79% | |
| ₹215.52 | ₹222.00 | ₹190.10 | ₹192.61 | -10.63% | |
| ₹224.10 | ₹230.00 | ₹195.00 | ₹215.52 | -3.83% | |
| ₹219.27 | ₹225.49 | ₹211.00 | ₹222.84 | +1.63% | |
| ₹234.55 | ₹255.63 | ₹208.00 | ₹219.27 | -6.51% | |
| ₹286.85 | ₹288.50 | ₹229.50 | ₹233.85 | -18.48% | |
| ₹223.77 | ₹301.65 | ₹221.21 | ₹285.03 | +27.38% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Jagsonpal's buyback is a short-term sugar rush masking potential margin pressures.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Jagsonpal Pharma announced a Cr share buyback program on March 12, 2026, at /share, representing a premium of over 43% to the then-current market price. The buyback involves 16 lakh shares, or 2.39% of total outstanding. Postal ballot notice was dispatched on March 26, with e-voting open until April 24, 2026. The company also announced closure of its trading window from April 1, 2026, ahead of FY26 results.
CORE STORY (THE REAL GAME)
Jagsonpal is playing the shareholder value unlock game. The buyback announcement is the key event, signaling management's confidence and an attempt to improve ROCE. The market is watching if Jagsonpal can sustain margins amidst pricing pressure in the Indian pharma sector.
- ₹40 Cr buyback at ₹250 offers near-term support
- Promoters signaling confidence by not participating in buyback
- Healthy cash position supports buyback and future M&A
- Strong Q4 results reversing Q3 weakness
- Successful inorganic growth initiatives
- Increased FII/DII interest
- Weak Q3FY26 results with significant profit decline
- Small-cap liquidity risk
- Dependence on specific therapeutic areas
FII and DII holdings are minimal, suggesting limited institutional interest. Promoter holding is high at 67.54%, increasing to 68.9% post buyback.
Indian pharma sector projected to reach $130 billion by 2030, but faces pricing pressures and supply chain issues.
Free Cash Flow 5Y: ₹207.42 Cr, indicating decent cash generation.
Next 3-6 months depend on Q4 results and successful execution of the buyback. Watch for margin trends and any M&A activity.
Primary Thesis Risk
Margin erosion and small-cap illiquidity can kill the buyback thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Jagsonpal Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Jagsonpal Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of JAGSNPHARM across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (18.58%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (22.95%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Excellent EPS Growth (37.78% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (38.15% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (54.51x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹207.42 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (67.54%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 2.20%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Jagsonpal Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Jagsonpal Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Jagsonpal Pharmaceuticals LtdJagsonpal Pharm...Selected✓ JAGSNPHARM • 507789 | 59.9/100 | ₹209.19₹209 | ₹1453.76₹1453.76 | 33.23Average 33.2 Average | 18.58%Good 18.58% Good | 22.95%Excellent 22.95% Excellent | 0.03Excellent 0.0 Excellent | 38.15%Excellent 38.15% Excellent | 11.13%Good 11.13% Good | 1.15% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1788.50₹1789 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6576.50₹6577 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4368.50₹4369 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1375.20₹1375 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1263.30₹1263 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2261.20₹2261 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1076.60₹1077 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2369.50₹2370 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1440.40₹1440 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5274.00₹5274 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Jagsonpal Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for JAGSNPHARM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹8.22 | ₹192.61 | 23.4x |
| FY 2024 | ₹3.39 | ₹244.34 | 72.1x |
| FY 2023 | ₹4.08 | ₹155.56 | 38.1x |
| FY 2022 | ₹2.88 | ₹149.10 | 51.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Jagsonpal Pharmaceuticals Ltd Dividend History
Annual cash dividends paid by JAGSNPHARM — dividend yield 1.15%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹13.23 Cr |
| FY 2024 | ₹13.10 Cr |
| FY 2022 | ₹10.48 Cr |
| FY 2021 | ₹2.62 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Jagsonpal Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for JAGSNPHARM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-0.29%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
9.69%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.13%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
38.15%
Compounded annual net profit growth over 5 years
Jagsonpal Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for JAGSNPHARM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Jagsonpal Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Jagsonpal Pharmaceuticals Ltd
About JAGSNPHARM (Jagsonpal Pharmaceuticals Ltd)
Jagsonpal Pharmaceuticals Ltd is a distinguished pharmaceutical company that has etched its mark on the healthcare landscape. With a steadfast commitment to innovation and quality,... Jagsonpal specializes in the development, production, and distribution of a diverse range of pharmaceutical products. The company's extensive portfolio encompasses formulations that cater to various therapeutic areas, addressing critical healthcare needs. Through rigorous research and development efforts, Jagsonpal remains at the forefront of pharmaceutical advancements, ensuring that patients have access to effective and cutting-edge treatments. Their products, known for their efficacy and reliability, are trusted by healthcare professionals and patients alike. The company continually strives to improve patient outcomes and contribute to the overall well-being of society. Driven by a dedication to excellence, Jagsonpal Pharmaceuticals operates with state-of-the-art manufacturing facilities and adheres to stringent quality control measures. This meticulous approach ensures that every product meets the highest industry standards and regulatory requirements. From sourcing premium ingredients to employing advanced manufacturing techniques, Jagsonpal maintains unwavering control over the entire production process. Their focus on quality extends beyond manufacturing, encompassing all aspects of the business, including customer service and ethical practices. This commitment to quality has earned Jagsonpal a strong reputation for integrity and trustworthiness within the pharmaceutical industry. Jagsonpal Pharmaceuticals distinguishes itself through its patient-centric approach, placing the needs and well-being of individuals at the heart of its operations. The company's dedication to improving lives is evident in its focus on developing innovative therapies and making them accessible to those who need them most. Furthermore, Jagsonpal is committed to sustainability and responsible business practices, recognizing the importance of environmental stewardship and ethical conduct. With a strong legacy of pharmaceutical excellence and a forward-looking vision, Jagsonpal Pharmaceuticals is poised to continue making a significant contribution to healthcare for generations to come.
Company Details
Key Leadership
Corporate Events
JAGSNPHARM Share Price: Frequently Asked Questions
What is the current share price of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) trades at ₹209.19 on NSE and BSE. Market cap ₹1.45K (Cr). Educational data only.
What is the P/E ratio of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd has a P/E of 33.23x vs industry average 31.77x.
What is the Bull Run score for Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd has a Bull Run score of 59.9/100 based on 25+ financial parameters.
Does Jagsonpal Pharmaceuticals Ltd pay dividends?
Jagsonpal Pharmaceuticals Ltd has a dividend yield of 1.15%. Past dividends don't guarantee future payments.
What is the ROE of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd has ROE of 18.58%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd has debt-to-equity of 0.03.
Is Jagsonpal Pharmaceuticals Ltd a good investment?
Bull Run gives Jagsonpal Pharmaceuticals Ltd a score of 59.9/100. This is not investment advice — consult a SEBI-registered advisor.